AZithromycin Against pLacebo in Exacerbations of Asthma (AZALEA)
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date ICMJE | September 22, 2011 | ||||||||
Last Updated Date | June 14, 2012 | ||||||||
Start Date ICMJE | September 2011 | ||||||||
Estimated Primary Completion Date | August 2012 (final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
Diary card summary symptom score [ Time Frame: 10 days after randomisation ] [ Designated as safety issue: Yes ] Symptoms include wheezing, breathlessness and coughing assessed at 10 days after randomisation. |
||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||
Change History | Complete list of historical versions of study NCT01444469 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||
Current Other Outcome Measures ICMJE | |||||||||
Original Other Outcome Measures ICMJE | |||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | AZithromycin Against pLacebo in Exacerbations of Asthma | ||||||||
Official Title ICMJE | A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients With Acute Exacerbations of Asthma | ||||||||
Brief Summary | Acute attacks (exacerbations) of asthma are common and cause a great deal of suffering in asthmatic patients. Current treatments for asthma attacks are not completely effective and new and better treatments are needed. Viruses often cause asthma attacks and bacterial lung infections have also been associated with asthma attacks. However, the role for bacteria is uncertain. Current asthma guidelines for doctors treating asthma exacerbations do not recommend the routine use of antibiotics. The investigators would like to investigate whether or not azithromycin, which is a safe and well tolerated antibiotic (an antibacterial) that has been used for many years in the treatment of respiratory disease, might be of benefit in asthma attacks. As there is some evidence that azithromycin has anti-viral properties this may add to its benefits (antibiotics don't usually affect viruses). By looking at the effect of azithromycin on asthma attacks this will help us to show whether or not azithromycin should be recommended during an acute asthma attack in addition to the usual care that is provided to these patients as it may help them recover quicker from the exacerbation. The investigators will also be able to look at why azithromycin may be effective - if it is having an anti-bacterial and/or anti-viral effect. |
||||||||
Detailed Description | |||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase | Phase 4 | ||||||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||||||
Condition ICMJE | Asthma | ||||||||
Intervention ICMJE |
|
||||||||
Study Arm (s) |
|
||||||||
Publications * | |||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE | 380 | ||||||||
Estimated Completion Date | May 2013 | ||||||||
Estimated Primary Completion Date | August 2012 (final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE | Inclusion Criteria: Patients meeting all of the following criteria will be considered for admission to the study:
Exclusion Criteria: Patients presenting with any of the following will not be included in the study:
|
||||||||
Gender | Both | ||||||||
Ages | 18 Years and older | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts ICMJE |
|
||||||||
Location Countries ICMJE | United Kingdom | ||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT01444469 | ||||||||
Other Study ID Numbers ICMJE | 2011-001093-26, 10/60/27 | ||||||||
Has Data Monitoring Committee | Yes | ||||||||
Responsible Party | Imperial College London | ||||||||
Study Sponsor ICMJE | Imperial College London | ||||||||
Collaborators ICMJE | National Institute for Health Research, United Kingdom | ||||||||
Investigators ICMJE |
|
||||||||
Information Provided By | Imperial College London | ||||||||
Verification Date | June 2012 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |